The novel human gene aprataxin is directly involved in DNA single-strand-break repair

Cellular and Molecular Life Sciences

Volumn 62, Issue 4, 2005, Pages 485-491

  Mosesso, P ^a   Piane, M ^b   Palitti, F ^a   Pepe, G ^a   Penna, S ^a   Chessa, L ^b  

^a UNIVERSITY OF TUSCIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Aprataxin; Camptothecin; Chromosomal aberration; DNA single strand break repair; Inhibitor of DNA topoisomerase I

Indexed keywords

APRATAXIN; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; NUCLEAR PROTEIN; SINGLE STRANDED DNA; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; COMET ASSAY; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; FEMALE; GENE MUTATION; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERSENSITIVITY; IONIZING RADIATION; MALE; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; WILD TYPE; X RAY;

APRAXIA, IDEOMOTOR; CAMPTOTHECIN; CEREBELLAR ATAXIA; CHROMOSOME ABERRATIONS; COMET ASSAY; DIAGNOSIS, DIFFERENTIAL; DNA DAMAGE; DNA REPAIR; DNA TOPOISOMERASES, TYPE I; DNA, SINGLE-STRANDED; DNA-BINDING PROTEINS; HUMANS; MALE; NUCLEAR PROTEINS; PEDIGREE; POINT MUTATION; RADIATION TOLERANCE; X-RAYS;

ATAXIA;

EID: 15044357229     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-004-4441-0     Document Type: Article

References (33)

1. Date H., Onodera O., Tanaka H., Iwabuchi K., Uekawa K., Igarashi S. et al. (2001) Early-onset ataxia with ocular motor apraxia and hypoalbuminemia is caused by mutations in a new HIT superfamily gene. Nat. Genet. 29: 184-188
2. Moreira M. C., Barbot C., Tachi N., Kozuka N., Uchida E., Gibson T. et al. (2001) The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. Nat. Genet. 29: 189-193
3. Taylor A. M., Harnden D. G., Arlett C. F., Harcourt S. A., Lehmann A. R., Stevens S. et al. (1975) Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 258, 427-429
4. Chen P. C., Lavin M. F., Kidson C. and Moss D. (1987) Identification of ataxia telangiectasia heterozygotes, a cancer prone population. Nature 274: 484-486
5. Lavin M. F. and Shiloh Y. (1997) The genetic defect in ataxia telangiectasia. Annu. Rev. Immunol. 15: 177-202
6. Shiloh Y. and Kastan M. B. (2001) ATM: genome stability, neuronal development and cancer cross paths. Adv. Cancer Res. 83: 209-254
7. Adamson A. W., Kim W. J., Shangary S., Baskaran R. and Brown K. D. (2002) ATM is activated in response to MNNG-induced DNA alkylation. J. Biol. Chem. 277: 38222-38229
8. Gueven N., Becherel O. J., Kijas A. W., Chen P., Howe O., Rudolph J. H. et al. (2004) Aprataxin, a novel protein that protects against genotoxic stress. Hum. Mol. Genet. 15: 1081-1093
9. Brenner C. (2002) Hint, Fhit, and GalT: function, structure, evolution, and mechanism of three branches of the histidine triad superfamily of nucleotide hydrolases and transferases. Biochemistry 23: 9003-9014
10. Moreira M. C., Barbot C., Tachi N, Kozuka N., Mendonca P., Barros J. et al. (2001) Homozygosity mapping of Portuguese and Japanese forms of ataxia-oculomotor apraxia to 9p13, and evidence for genetic heterogeneity. Am. J. Hum. Genet. 68: 501-508
11. Zwelling L. A., Michaels S., Erickson L. C., Ungerleider R. S., Nichols M. and Kohn K. W. (1981) Protein-associated deoxyribonucleic acid intercalating agents 4′-(9-acridylamino)methanesulfon-m-anisidine and adriamycin. Biochemistry 20: 6553-0563
12. Zwelling L. A. (1985) DNA topoisomerase II as a target of antineoplastic drug therapy. Cancer Metast. Rev. 4: 263-276
13. Glisson R. C. and Ross W. E. (1987) DNA topoisomerase II: a primer on the enzyme and its unique role as multidrug target in cancer chemotherapy. Pharmacol. Ther. 32: 89-106
14. Degrassi F., De Salvia R., Tanzarella C. and Palitti F. (1989) Induction of chromosomal aberrations and SCE by camptothecin, an inhibitor of mammalian topoisomerase I. Mutat. Res. 211: 125-130
15. Dillehay L. E., Thompson L. H., Minkler J. L. and Carrano A. V. (1983) The relationship between sister-chromatid exchange and perturbations in DNA replication in mutant EM9 and normal CHO cells. Mutat. Res. 109: 283-296
16. D'Arpa P. and Liu F. L. (1989) Topoisomerase-targeting antitumour drugs. Biochem. Biophys. Acta 989: 163-177
17. Hsiang Y. H., Lihou M. G. and Liu F. L. (1989) Arrest of replication forks by drug-stabilised topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49: 5077-5082
18. Zhang H., D'Arpa P. and Liu F. L. (1990) A model for tumour cell killing by topoisomerase poisons. Cancer Cells 2: 23-27
19. Ryan A. J., Squires S., Strutt H. L. and Johnson R. T. (1991) Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double-strand breaks in replicating DNA. Nucleic Acids Res. 19: 3295-3300
20. Oefner P. J. and Underhill P. A. (1999) DNA mutation detection using denaturing high-performance liquid chromatography (DHPLC). In: Current Protocols in Human Genetics, Suppl. 19, pp 7.10.1-7.10.12, Dracopoli N. C., Haines J., Korf B. R., Morton C., Seidman C. E., Seidman J. G. et al. (eds) Wiley-Interscience, New York
21. Oefner P. J. (2000) Allelic discrimination by denaturing high-performance liquid chromatography. J. Chromatogr. B. Biomed. Sci. Appl. 739: 345-355
22. Xiao W. and Oefner P. J. (2001 ) Denaturing high-performance liquid chromatography: a review. Hum. Mut. 17: 439-474
23. Savage J. R. (1977) Application of chromosome banding techniques to the study of primary chromosome structural changes. J. Med. Genet. 14: 362-370
24. Singh N. P., McCoy M. T., Tice R. R. and Schneider E. L. (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175: 184-191
25. Barrows L. R., Paxton M. B., Kennedy K. A. and Thompson L. H. (1991) XRCC1 gene expression andphenotypes of revertant EM9 (CHO) cell lines. Carcinogenesis 12: 805-811
26. Park S. Y., Lam W. and Cheng Y. C. (2002) X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res. 15: 459-465
27. Thompson L. H., Brookman K. W., Jones N. J., Allen S. A. and Carrano A. V. (1990) Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchanges. Mol. Cell Biol. 10: 6160-6171
28. Caldecott K. W:, Aoufouchi S., Johnson P. and Shall S. (1996) XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly(ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro. Nucleic Acid Res. 24: 4387-4394
29. Burkle A. (2001) Physiology and pathophysiology of poly-(ADP-ribosyl) ation. Bioassays 23: 795-806
30. 2 stage of the cell cycle. Mutat. Res. 52: 137-149
31. Preston R. J. (1980) The effect of cytosine arabinoside on the frequency of X-ray induced chromosome aberrations in normal human leukocytes. Mutat. Res. 69: 71-79
32. Preston R. J. and Gooch (1981) The induction of chromosome-type aberrations in G1 by methyl methanesulphonate and 4-nitroquinoline-N-oxide, and the non-requirement of an S-phase for their production. Mutat. Res. 83: 395-402
33. Clements P. M., Breslin C., Deeks E. D., Byrd P. J., Ju L., Bieganowski P. et al. (2004) The ataxia-oculomotor apraxia 1 gene product has a role distinct from ATM and interacts with the DNA strand break repair proteins XRCC1 and XRCC4. DNA Repair 3: 1493-1502